Loading...
Market
What will be the outcome of Editas in-vivo sickle cell therapy trials by end of 2025?
2
Resolution / Starting Odds
Successful • 25%
Partially Successful • 25%
Unsuccessful • 25%
No Data Released • 25%
Official press releases from Editas Medicine or peer-reviewed publications
Story
Editas Shifts to In-Vivo Gene Therapy for Sickle Cell, Signs $238 Million Biobucks Pact
Oct 22, 2024, 12:22 PM
Editas Medicine has announced a significant strategic shift by halting the development of its ex-vivo treatment for sickle cell disease (SCD) and beta-thalassemia. The company will now focus on an in-vivo approach, which involves editing a patient's genes within the body using LNP delivery. This pivot is seen as a more scalable but riskier strategy. Editas aims to achieve proof-of-concept data and has signed a $238 million biobucks pact to support this new direction. The company is also seeking a partner for its more advanced ex-vivo sickle cell treatment, which has shown data equivalent to Casgevy and Lyfgenia.
View original story
Similar markets
Yes • 50%
No • 50%
Proof-of-concept data achieved • 25%
Partnership announcement • 25%
Regulatory approval submission • 25%
No major milestone achieved • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Editas Medicine • 25%
Intellia Therapeutics • 25%
CRISPR Therapeutics • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 1% • 25%
1% to 5% • 25%
5% to 10% • 25%
More than 10% • 25%
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Yes • 50%
No • 50%
Full agreement executed • 25%
Partial execution • 25%
Agreement terminated • 25%
No significant progress • 25%